Drug-induced nail abnormalities can present with a wide variety of clinical manifestations that are often dose-related and that disappear after drug withdrawal. Some nail changes are asymptomatic and only cause cosmetic problems, whereas others cause pain and discomfort and impair manual activities or deambulation. New side effects have been recently observed with different groups of anticancer agents. These include painful onycholysis and subungual abscesses caused by taxanes and anthracyclines (eg, doxorubicin) in addition to ingrown nails, paronychia, and pyogenic granuloma associated with the use of tyrosine kinase inhibitors of the epidermal growth factor receptor (eg, erlotinib, gefitinib).
Piraccini BM, Alessandrini A. (2013). Drug-related nail disease. CLINICS IN DERMATOLOGY, 31(5), 618-626 [10.1016/j.clindermatol.2013.06.013].
Drug-related nail disease
PIRACCINI, BIANCA MARIA;ALESSANDRINI, AURORA MARIA
2013
Abstract
Drug-induced nail abnormalities can present with a wide variety of clinical manifestations that are often dose-related and that disappear after drug withdrawal. Some nail changes are asymptomatic and only cause cosmetic problems, whereas others cause pain and discomfort and impair manual activities or deambulation. New side effects have been recently observed with different groups of anticancer agents. These include painful onycholysis and subungual abscesses caused by taxanes and anthracyclines (eg, doxorubicin) in addition to ingrown nails, paronychia, and pyogenic granuloma associated with the use of tyrosine kinase inhibitors of the epidermal growth factor receptor (eg, erlotinib, gefitinib).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.